| Literature DB >> 34370174 |
Dimitrios Kalogeropoulos1, Hercules Sakkas2, Bashar Mohammed3, Georgios Vartholomatos4, Konstantinos Malamos5, Sreekanth Sreekantam3, Panagiotis Kanavaros6, Chris Kalogeropoulos5.
Abstract
PURPOSE: This review aims to summarize the current knowledge concerning the clinical features, diagnostic work-up and therapeutic approach of ocular toxoplasmosis focusing mainly on the postnatally acquired form of the disease.Entities:
Keywords: Ocular toxoplasmosis; Posterior uveitis; Retinochoroiditis; Toxoplasma gondii
Mesh:
Year: 2021 PMID: 34370174 PMCID: PMC8351587 DOI: 10.1007/s10792-021-01994-9
Source DB: PubMed Journal: Int Ophthalmol ISSN: 0165-5701 Impact factor: 2.031
Fig. 1a Active toxoplasmic retinitis (red arrow) with a slightly hazed overlying vitreous. Note the presence of a mild neuroretinitis. b B-Mode of the same patient showing focal vitritis (yellow arrows) near the active lesion (red arrow)
Fig. 2A new active lesion of retinitis (yellow arrow) due to recurrence of toxoplasmic retinochoroiditis, adjacent to older lesions (scarred areas with pigmentation)
Fig. 3Kyrieleis arteritis in toxoplasmic retinochoroiditis presenting as a segmental intravascular white plaque (black arrow). The active retinochoroidal lesion is indicated by the white arrow
Fig. 4Patient of Fig. 2, 8 years after the last recurrence of toxoplasmic retinochoroiditis. a Macular hole (white arrow) adjacent to severe old lesions. b Optical coherence tomography (OCT) scan with a characteristic imaging of a full-thickness macular hole
Fig. 5a Indocyanine green angiography (ICGA) of a patient with punctate outer retinal toxoplasmosis (significantly elevated IgG titers). Note the hypofluorescent punctate lesions (white arrow) and the neovascular choroidal membrane (red arrow) as a complication of the inflammatory process. b Optical coherence tomography (OCT) of the same patient with vitreous hyperreflective spots or hyaloid bodies (white arrow) and subretinal exudative fluid (red arrow) due to the adjacent neovascular membrane
Fig. 6Retinal imaging in a patient with ocular toxoplasmosis. a Primary acute toxoplasmic retinitis without other lesions in the surrounding area. b In the arterial phase of fluoroangiography (FA) a masking effect corresponds to the inflamed retina. c In the mid-venous FA phase vasculitis is indicated by a red arrow. d Hyperfluorescence of the inflammatory lesion during the transit FA phase (leakage from the dilated vessels in the area of the lesion). Note that the optic disk is also involved
Serological tests for Toxoplasma gondii infections
| Name of serological test | Advantages | Disadvantages | Special features |
|---|---|---|---|
| Sabin-Feldman dye test (DT) | Still considered the gold standard test of toxoplasma serology Highly sensitive, specific, and quantitative | It can only be carried out in reference centers due to the requirement for live tachyzoites, which are amplified in mouse peritoneum or cell culture | The first test developed for the laboratory diagnosis of |
| Indirect fluorescent assay (IFA) | More economical and safer to perform than DT, measuring the same antibodies as the DT Test results are easy to evaluate visually IFA has proved to be specific | The interpretation is subjective and time-consuming Lower sensitivity compared to the DT False-positive results may occur | The IFA requires the use of a fluorescence microscope |
| Direct agglutination test | The direct agglutination test needs no special equipment or conjugates A sensitive, specific, and useful assay that shows good correlation with the DT | Non-specific immunoglobulins interfere with the test * (but they can be removed by treatment with mercaptoethanol and enzymatic treatment) | Measurement of IgG antibodies to Toxoplasma that react with the membrane antigen |
| Differential agglutination test (HS/AC test) | The AC antigen preparation involves stage-specific antigens that are preferentially detected by IgG antibodies formed against Toxoplasma tachyzoites at the early stages of infection | – | Sera from individuals with acute infection tended to agglutinate both the HS and AC parasite suspensions Higher titers in the HS agglutination test and lower or negative titers in the AC agglutination were found in in cases which acquired infection in the distant past |
| Latex agglutination test and indirect agglutination test (LAT) | Easy to perform and sensitive | Issues with its specificity | The antibody response in acute infections may not be detected for many weeks, showing the predominance of cytoplasmic antigens present in the assays |
| The immunosorbent agglutination assay (ISAGA) | A highly specific test for the detection of anti-T. gondii IgM, IgA, or IgE antibodies One the most sensitive commercially available Toxoplasma serologic tests | It requires a high degree of expertise and is not automated | Used in reference centers, and usually in neonates suspected of having a congenital infection Also applied for the detection of IgE and IgA |
| Enzyme immunoassays (EIA) | The most common laboratory Toxoplasma diagnostic test [ELISA and the enzyme-linked fluorescent immunoassay (ELFA) are the two most common EIAs] Available as commercial kits and automated platforms Fast and low-cost screening tests Improved to avoid false-positive results | Poor standardization due to variations in antigen quality and consequent variable results | The use of recombinant antigens reduces the cost and labor required for the production of diagnostic tests |
| IgG avidity test | Used to discriminate recently acquired infections from those that occurred in the more distant past The presence of high avidity antibodies is a reliable marker of chronic infection Very useful in pregnant women with positive IgG and IgM titers at their first antenatal visit (during the first trimester of pregnancy) | Further serologic techniques should be applied when low or borderline avidity results are encountered | No universal threshold has been defined above which avidity is confirmed to be high (most laboratories apply their own interpretation according to their requirements) |
| Immunochromatographic tests (ICT) | Point-of-care testing Cost-effective User-friendly format Fast time results | Low sensitivity and specificity | Useful as a screening test |
| Western blotting | Diagnosis congenital infection in newborns A highly sensitive and specific method for the reliable detection of Toxoplasma infection as a confirmatory test | – | Very useful for the follow-up testing of pregnant women and their infants or for immunodeficient individuals after HIV infection, malignancies, or organ transplantation |
References: [7, 122–135]
AC antigen, acetone- or methanol-fixed tachyzoites; HIV, human immunodeficiency virus; HS antigen, formalin-fixed tachyzoites; Ig, immunoglobulin
Available drug options for toxoplasmosis
| Medication | Adult dose | Pediatric dose |
|---|---|---|
| Pyrimethamine | Loading dose: 100 mg (1st day) Treatment dose: 25 mg twice daily for 4–6 weeks | 1. Infants 1 mg/kg once daily for 1 year 2. Children Loading dose: 2 mg/kg/day divided into 2 daily doses for 1–3 days (maximum: 100 mg/day) Treatment dose: 1 mg/kg/day divided into 2 doses for 4 weeks; (maximum: 25 mg/day) |
| Folinic acid | 15 mg daily | 5 mg every 3 days |
| Trimethoprime—sulfamethoxazol | One tablet twice daily for 4–6 weeks | 6–12 mg TMP/kg/day in divided doses every 12 h |
| Sulfadiazine | 4 g daily divided every 6 h | 3. Congenital toxoplasmosis Newborns and Children < 2 months: 100 mg/kg/day divided every 6 h Children > 2 months: 25–50 mg/kg/dose 4 times/day 4. Toxoplasmosis in children > 2 months Loading dose: 75 mg/kg Treatment dose: 120–150 mg/kg/day, divided every 4–6 h (maximum dose: 6 g/day) |
| Clindamycin | 150–450 mg/dose every 6–8 h (maximum dose: 1.8 g/day) (usually 300 mg every 6 h) | 8–25 mg/kg/day in 3–4 divided doses |
| Azithromycin | Loading dose: 1 g (1st day) Treatment dose: 500 mg once daily for 3 weeks | Children ≥ 6 months: 10 mg/kg on first day (maximum: 500 mg/day) followed by 5 mg/kg/day once daily (maximum: 250 mg/day) |
| Spiramycin | 2 g per day in two divided doses | 15 kg = 750 mg 20 kg = 1 g 30 kg = 1.5 g |
| Atovaquone | 750 mg every 6 h for 4–6 weeks | 40 mg/kg/day divided twice daily (maximum dose: 1500 mg/day) |
| Tetracycline | Loading dose: 500 mg every 6 h (first day) Treatment dose: 250 mg every 6 h for 4–6 weeks | Children > 8 years: 25–50 mg/kg/day in divided doses every 6 h |
| Minocycline | 100 mg every 12 h not to exceed 400 mg/24 h for 4 to 6 weeks | Children > 8 years Initial: 4 mg/kg followed by 2 mg/kg/dose every 12 h (Oral, I.V.) |
g, gram; I.V., intravenous, kg, kilogram; mg, milligram, TMP, trimethoprime
Modified from Bonfioli and Orefice [123] and readjusted according to the protocols of the Department of Ophthalmology (Ocular Inflammation Service) of the University Hospital of Ioannina, Greece
Fig. 7A 67-year-old lady with positive serology for toxoplasma (IgM and IgG both positive) with intense and resistant to the treatment inflammation. Taking into consideration the age of the patient the possibility of primary vitreoretinal lymphoma was ruled out using vitreous flow cytometry. a Lesion of acute toxoplasmic retinochoroiditis (white arrow) and dense vitritis obscuring the fundus details. b–d Representative plots of immunophenotyping by three color analysis flow cytometry. It is possible accurately to distinguish lymphocytes from other leukocyte and other cells populations in vitreous humor using the combination of fluorescence associated with CD45 PerCP/SSC and orthogonal light scatter. By identifying the cell population of interest based on immunofluorescence, a light scattering window can then be drawn to include all (≥ 95%) of the lymphocytes (Gate 1). In this manner, maximal recovery of the lymphocytes within a sample can be consistently obtained. The combination of light scattering and immunofluorescence can also be used to define the purity of the gate. The identification of non-lymphocytes (CD45PerCP negative) within the light scattering gate can then be used to establish an accurate denominator for the percent lymphocytes stained with CDs. b Bivariate histogram CD45/SSC with three gates: gate R1 including lymphocytes (red), gate R2 monocytes and macrophages (green), gate R3 Debris (non-leukocytes, apoptotic /necrotic cells) (purple). c Bivariate histogram CD3 PE/CD19 FITC in the R1 gate of Lymphocytes: T-Lymphocytes CD3 + (95%), B- Lymphocytes CD19 + (00%). d Bivariate histogram CD4 PE/CD8 FITC in the R1 gate of Lymphocytes: T helper cells (Th cells) CD4 + (57%), T cytotoxic (Tc cells) CD8 + (25%), and double positive T-cells CD4 + CD8 + (14%)
Available drug options for toxoplasmosis
| Medication | Adult dose | Pediatric dose |
|---|---|---|
| Pyrimethamine | Loading dose: 100 mg (1st day) Treatment dose: 25 mg twice daily for 4–6 weeks | Infants 1 mg/kg once daily for 1 year Children Loading dose: 2 mg/kg/day divided into 2 daily doses for 1–3 days (maximum: 100 mg/day) Treatment dose: 1 mg/kg/day divided into 2 doses for 4 weeks; (maximum: 25 mg/day) |
| Folinic acid | 15 mg daily | 5 mg every 3 days |
| Trimethoprime—sulfamethoxazol | One tablet twice daily for 4–6 weeks | 6–12 mg TMP/kg/day in divided doses every 12 h |
| Sulfadiazine | 4 g daily divided every 6 h | Congenital toxoplasmosis Newborns and Children < 2 months: 100 mg/kg/day divided every 6 h Children > 2 months: 25–50 mg/kg/dose 4 times/day Toxoplasmosis in children > 2 months Loading dose: 75 mg/kg Treatment dose: 120–150 mg/kg/day, divided every 4–6 h (maximum dose: 6 g/day) |
| Clindamycin | 150–450 mg/dose every 6–8 h (maximum dose: 1.8 g/day) (usually 300 mg every 6 h) | 8–25 mg/kg/day in 3–4 divided doses |
| Azithromycin | Loading dose: 1 g (1st day) Treatment dose: 500 mg once daily for 3 weeks | Children ≥ 6 months: 10 mg/kg on first day (maximum: 500 mg/day) followed by 5 mg/kg/day once daily (maximum: 250 mg/day) |
| Spiramycin | 2 g per day in two divided doses | 15 kg = 750 mg 20 kg = 1 g 30 kg = 1.5 g |
| Atovaquone | 750 mg every 6 h for 4–6 weeks | 40 mg/kg/day divided twice daily (maximum dose: 1500 mg/day) |
| Tetracycline | Loading dose: 500 mg every 6 h (first day) Treatment dose: 250 mg every 6 h for 4–6 weeks | Children > 8 years: 25–50 mg/kg/day in divided doses every 6 h |
| Minocycline | 100 mg every 12 h not to exceed 400 mg/24 h for 4 to 6 weeks | Children > 8 years Initial: 4 mg/kg followed by 2 mg/kg/dose every 12 h (Oral, I.V.) |
g, gram; I.V., intravenous; kg, kilogram; mg, milligram; TMP, trimethoprime
Modified from: Bonfioli and Orefice [99] and readjusted according to the protocols of the Department of Ophthalmology (Ocular Inflammation Service) of the University Hospital of Ioannina, Greece